JP2021520830A - Cd47タンパク質に結合する融合タンパク質およびその使用 - Google Patents
Cd47タンパク質に結合する融合タンパク質およびその使用 Download PDFInfo
- Publication number
- JP2021520830A JP2021520830A JP2020556859A JP2020556859A JP2021520830A JP 2021520830 A JP2021520830 A JP 2021520830A JP 2020556859 A JP2020556859 A JP 2020556859A JP 2020556859 A JP2020556859 A JP 2020556859A JP 2021520830 A JP2021520830 A JP 2021520830A
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- amino acid
- domain
- present
- sirpα
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 149
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 147
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 title claims abstract description 133
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 title claims abstract description 126
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims abstract description 136
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims abstract description 136
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 63
- 230000027455 binding Effects 0.000 claims abstract description 31
- 230000003993 interaction Effects 0.000 claims abstract description 25
- 238000006243 chemical reaction Methods 0.000 claims abstract description 22
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 20
- 230000023555 blood coagulation Effects 0.000 claims abstract description 15
- 230000012010 growth Effects 0.000 claims abstract description 9
- 230000035755 proliferation Effects 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 106
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 77
- 150000001413 amino acids Chemical group 0.000 claims description 49
- 239000012634 fragment Substances 0.000 claims description 42
- 239000013598 vector Substances 0.000 claims description 41
- 102000039446 nucleic acids Human genes 0.000 claims description 40
- 108020004707 nucleic acids Proteins 0.000 claims description 40
- 150000007523 nucleic acids Chemical class 0.000 claims description 40
- 108060003951 Immunoglobulin Proteins 0.000 claims description 31
- 102000018358 immunoglobulin Human genes 0.000 claims description 31
- 238000006467 substitution reaction Methods 0.000 claims description 28
- 125000000539 amino acid group Chemical group 0.000 claims description 27
- 102220283728 rs1064794204 Human genes 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 102200153332 rs116840818 Human genes 0.000 claims description 18
- 102220580619 Porphobilinogen deaminase_K98R_mutation Human genes 0.000 claims description 16
- 230000000903 blocking effect Effects 0.000 claims description 14
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 102220250763 rs147081785 Human genes 0.000 claims description 12
- 102220164353 rs375686155 Human genes 0.000 claims description 12
- 102000044459 human CD47 Human genes 0.000 claims description 9
- 102200118226 rs33959340 Human genes 0.000 claims description 8
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 201000005787 hematologic cancer Diseases 0.000 claims description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 201000009961 allergic asthma Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 102200047012 rs104894934 Human genes 0.000 claims description 3
- 102220488187 Olfactory receptor 2A12_I29L_mutation Human genes 0.000 claims description 2
- 102220582332 Porphobilinogen deaminase_R22C_mutation Human genes 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 102220093685 rs374006397 Human genes 0.000 claims 1
- 102200091898 rs77050410 Human genes 0.000 claims 1
- 238000010586 diagram Methods 0.000 abstract description 3
- 235000001014 amino acid Nutrition 0.000 description 64
- 229940024606 amino acid Drugs 0.000 description 45
- 108090000623 proteins and genes Proteins 0.000 description 37
- 229940126302 TTI-621 Drugs 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 29
- 210000003743 erythrocyte Anatomy 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 26
- 230000000694 effects Effects 0.000 description 22
- 102220553770 Cyclic GMP-AMP synthase_K83R_mutation Human genes 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 229920001184 polypeptide Polymers 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 210000001772 blood platelet Anatomy 0.000 description 14
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 102220577898 Tyrosine-protein phosphatase non-receptor type substrate 1_L96S_mutation Human genes 0.000 description 12
- 102220492708 Protein phosphatase 1 regulatory subunit 7_E77Q_mutation Human genes 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 102220230344 rs1064794204 Human genes 0.000 description 10
- 102220070934 rs794728586 Human genes 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 102220483802 Aminopeptidase RNPEPL1_E84G_mutation Human genes 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 description 8
- 102220577895 Tyrosine-protein phosphatase non-receptor type substrate 1_D95E_mutation Human genes 0.000 description 8
- 102200078037 rs104895336 Human genes 0.000 description 8
- 201000000050 myeloid neoplasm Diseases 0.000 description 7
- 102220070933 rs794728602 Human genes 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102220481774 Kinesin-like protein KIF20A_I61F_mutation Human genes 0.000 description 6
- 102220384347 c.298A>G Human genes 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 210000001539 phagocyte Anatomy 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000005917 in vivo anti-tumor Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 208000014767 Myeloproliferative disease Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102220577892 Tyrosine-protein phosphatase non-receptor type substrate 1_E77K_mutation Human genes 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000035931 haemagglutination Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000003125 jurkat cell Anatomy 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 102220219557 rs1060501791 Human genes 0.000 description 4
- 102220188005 rs886053373 Human genes 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108091006020 Fc-tagged proteins Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 108010046722 Thrombospondin 1 Proteins 0.000 description 3
- 102100036034 Thrombospondin-1 Human genes 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
- 102220564808 Killer cell immunoglobulin-like receptor 2DL2_E77L_mutation Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 101710098610 Leukocyte surface antigen CD47 Proteins 0.000 description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 102220488422 Olfactory receptor 10H4_N100K_mutation Human genes 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 102200113220 rs35220041 Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- -1 serum Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 238000012492 Biacore method Methods 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102000006355 CD47 Antigen Human genes 0.000 description 1
- 108010058590 CD47 Antigen Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 101150022345 GAS6 gene Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000022435 Light chain deposition disease Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 101150117918 Tacstd2 gene Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003095 anti-phagocytic effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000028600 axonogenesis Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- SWKDMSRRIBZZAY-UHFFFAOYSA-N n-benzyl-n-(4,5-dihydro-1h-imidazol-2-ylmethyl)aniline;hydrochloride Chemical compound Cl.N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 SWKDMSRRIBZZAY-UHFFFAOYSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本発明は、CD47タンパク質に結合する融合タンパク質およびその使用に関するものである。上記融合タンパク質は、CD47タンパク質とSIRPαとの相互作用を特異的に遮断することができ、且つ血液凝固反応を起こすことがなく、さらに、腫瘍または腫瘍細胞の成長および/または増殖を抑制することができる。
CD47タンパク質は、免疫グロブリンスーパーファミリーメンバーに属し、赤血球を含めて多くの細胞表面に発現する膜貫通型糖タンパク質である。CD47の配位子は、インテグリン(intergrins)、トロンボスポンジンタンパク質1(thrombospondin-1)およびシグナル調節タンパク質(SIRPs)を含む。CD47は、細胞遊走、T細胞、樹状細胞活性化、軸索成長などを含めて複数種類の生物的機能に影響を与える。このほかには、CD47は、SIRPαとの相互作用によって貪食細胞による食作用を阻害し、血球などの正常細胞が貪食細胞により貪食されないように保護する。調べによれば、正常組織細胞によるCD47の発現のほか、多くの腫瘍細胞がCD47を過剰に発現し、また、貪食細胞表面のSIRPαに結合することによって貪食細胞の腫瘍細胞貪食を阻止し、これも、腫瘍の免疫監視逃避機構であることが分かった。CD47タンパク質とSIRPαの相互作用遮断によって、腫瘍増殖を抑制することができる(Theocharides APA, et al., 2012)。
本発明は、CD47タンパク質に結合する融合タンパク質およびその使用を提供する。上記融合タンパク質は、CD47タンパク質に特異的に結合することができる。本発明に記載の融合タンパク質は、1)高い親和力でCD47タンパク質に特異的に結合し、2)CD47タンパク質とSIRPαの相互作用を特異的に遮断し、3)血液凝固反応を起こすことがなく、4)腫瘍または腫瘍細胞の成長および/または増殖を抑制し、5)CD47/SIRPα相互作用によって誘導されるアポトーシスシグナルを阻害し、および/または、6)被験者に安全であり、体を傷害する副作用がない特性の少なくとも1種類を含む。本発明は、さらに、上記融合タンパク質の調製方法および使用を提供する。
本発明に係る具体的な特徴は、添付の請求項のように示されたものである。本発明に係る特徴やメリットは、以下詳しく記載されている例示的実施形態や図面を参照することによって、より確実的に把握されるだろう。図面に関しては、以下のように概略的に説明する。
図2は、SIRPα短縮ドメインおよびその突然変異体とCD47の間の相互作用を測定する方法模式図を示す。
図3は、SIRPα短縮ドメイン突然変異体のフローサイトメトリー濃縮スクリーニング結果を示す。
図4は、SIRPα短縮ドメインおよびその変異体の配列整列態様を示す。
図5は、本発明に記載の融合タンパク質がCD47タンパク質を認識した結果を示す。
図6A〜6Bは、本発明に記載の融合タンパク質がヒトCD47タンパク質を認識する特異性を示す。
図7は、本発明に記載の融合タンパク質によるヒトCD47タンパク質およびその他のタンパク質への認識の態様を示す。
図8は、本発明に記載の融合タンパク質がCD47タンパク質とその配位子SIRPαの結合をTTI-621と競合的に遮断することを示す。
図9A〜9Cは、本発明に記載の融合タンパク質がRaji細胞、Jurkat細胞およびA549細胞表面CD47タンパク質を認識した結果を示す。
図10A〜10Cは、本発明に記載の融合タンパク質およびTTI-621がRaji細胞、Jurkat細胞およびA549細胞表面CD47タンパク質を認識した結果を示す。
図11は、本発明に記載の融合タンパク質とHu5F9-G4との抗凝血反応の結果を示す。
図12A〜12Bは、本発明に記載の融合タンパク質による腫瘍活性の抑制を示す。
図13A〜13Bは、赤血球および血小板に対しての本発明に記載の融合タンパク質とTTI-621による影響を比較することを示す。
図14は、本発明に記載の融合タンパク質がCD47タンパク質を認識した結果を示す。
図15は、本発明に記載の融合タンパク質がCD47タンパク質とその配位子SIRPαの結合を競合的に遮断することを示す。
図16は、本発明に記載の融合タンパク質とHu5F9-G4との抗凝血反応の結果を示す。
図17は、本発明に記載の融合タンパク質がCD47-Fc誘導Jurkat-CSR細胞アポトーシスを効果的に遮断することを示す。
図18Aは、本発明に記載の融合タンパク質によるマウス末梢血における赤血球含有量への影響を示す。
図18Bは、本発明に記載の融合タンパク質によるマウス末梢血における血小板含有量への影響を示す。
図19は、本発明に記載の融合タンパク質によるマウスインビボ腫瘍増殖抑制役割を示す。
図20は、本発明に記載の融合タンパク質によるマウス体重への影響を示す。
以下、本願発明の実施形態を、所定の具体的な実施例によって説明するが、当業者が、本明細書に公開された内容により、本願発明のその他のメリットや効果を容易に把握することができる。
一方で、本発明は、CD47タンパク質に特異的に結合することができ、以1×10-8Mまたはより低いKD値、例えば、9×10-9Mよりも高くなく、8×10-9Mよりも高くなく、7×10-9Mよりも高くなく、6.2×10-9Mよりも高くなく、6×10-9Mよりも高くなく、5×10-9Mよりも高くなく、4.8×10-9Mよりも高くなく、4.5×10-9Mよりも高くなく、2×10-9Mよりも高くなく、1.5×10-9Mよりも高くなく、または1×10-10Mよりも高くなくまたはこれ以上低いKD値でCD47タンパク質に結合する融合タンパク質を提供する。
非極性側鎖を含むアミノ酸群:アラニン、バリン、ロイシン、イソロイシン、プロリン、フェニルアラニン、トリプトファンおよびメチオニン。
非帯電した極性側鎖を含むアミノ酸群:グリシン、セリン、トレオニン、システイン、チロシン、アスパラギンおよびグルタミン。
負帯電した極性側鎖を含むアミノ酸群:アスパラギン酸およびグルタミン酸。
正帯電した塩基性アミノ酸:リシン、アルギニンおよびヒスタジン。
フェニル基を持つアミノ酸:フェニルアラニン、トリプトファンおよびチロシン。
(1)I61L、V63I、E77I、E84K、V93L、L96S、K98R、N100GおよびV132L、
(2)I61V、E77N、Q82S、K83RおよびE84H、
(3)I61F、V63I、K83R、E84KおよびV132I、
(4)I61L、E77Q、E84D、R107NおよびV132I、
(5)I61L、V63I、E77K、K83R、E84DおよびN100G、
(6)I61V、E77H、Q82R、K83R、E84HおよびR107S、
(7)I61L、E77I、Q82G、E84R、V93L、L96T、N100G、R107S、G109RおよびV132R、
(8)I61L、E77M、Q82G、K83R、E84DおよびV132L、
(9)I61L、
(10)I61F、D95H、L96S、G109HおよびV132S、
(11)I61F、D95H、L96S、K98R、G109HおよびV132S、
(12)I61L、E77Q、E84D、V93A、R107NおよびV132I、
(13)E77K、L96S、N100K、G109HおよびV132L、
(14)I61L、V63I、Q82G、E84G、D95R、L96S、N100DおよびV132I、
(15)I61L、E77R、Q82N、K83R、E84G、V93L、D95E、L96T、K98R、N100DおよびV132L、
(16)I61V、E77N、Q82S、K83R、E84HおよびV93A、
(17)I61V、V63I、E77V、K83R、E84D、D95E、L96T、K98RおよびN100E、
(18)I61L、V63I、E77V、K83R、D95E、L96S、K98R、N100DおよびG109R、
(19)I61V、E77L、Q82G、E84G、V93L、D95E、L96T、K98RおよびN100G、および、
(20)I61L、V63I、E77N、Q82GおよびE84G、
から選ばれるアミノ酸置換群を有して良い。
その一方で、本発明は、本発明に記載の融合タンパク質をコードすることができる核酸分子を1種類または複数種類提供する。
一方で、本発明は、上記融合タンパク質を発現させる条件で、宿主細胞を培養することを含む、上記融合タンパク質を調製する方法を提供することができる。
実施例1 変異体の選別
アミノ酸配列が例えばSEQ ID NO:63(すなわち、SEQ ID NO:62中で33〜149番目の残基)で表されるヒトSIRPα変異体1(NP_542970.1)の短縮ドメインを取り、Discovery Studio(chuangtengテクノロジー)ソフトウェアで該短縮ドメインにおけるヒトCD47(CEJ95640.1)との相互作用の構造を構築し、2個のタンパク質における相互作用を関与する部位と相互作用モデルを理論に解析し、該短縮ドメインにおける直接または間接にCD47との相互作用を関与するアミノ酸部位がI61、V63、E77、Q82、K83、E84、V93、D95、D96、K98、N100、R107、G109、V132を特定した(ここで、これらのアミノ酸置換中でアミノ酸残基の位置が、SEQ ID NO: 62で表されるアミノ酸配列によるナンバリングカウントを行った)。これらの作用部位にランダム突然変異を引き起こし、突然変異体ライブラリーを構築した。そして、該突然変異体ライブラリーをベクターpTM上にクローンした。上記pTMベクターは、シグナルペプチド 、膜貫通領域配列(例えば図1に示された)を含み、細胞表面に該ベクターにクローンされた遺伝子を表現可能である。
(1)I61L、V63I、E77I、E84K、V93L、L96S、K98R、N100GおよびV132L、
(2)I61V、E77N、Q82S、K83RおよびE84H、
(3)I61F、V63I、K83R、E84KおよびV132I、
(4)I61L、E77Q、E84D、R107NおよびV132I、
(5)I61L、V63I、E77K、K83R、E84DおよびN100G、
(6)I61V、E77H、Q82R、K83R、E84HおよびR107S、
(7)I61L、E77I、Q82G、E84R、V93L、L96T、N100G、R107S、G109RおよびV132R、
(8)I61L、E77M、Q82G、K83R、E84DおよびV132L、
(9)I61L、
(10)I61F、D95H、L96S、G109HおよびV132S、
(11)I61F、D95H、L96S、K98R、G109HおよびV132S、
(12)I61L、E77Q、E84D、V93A、R107NおよびV132I、
(13)E77K、L96S、N100K、G109HおよびV132L、
(14)I61L、V63I、Q82G、E84G、D95R、L96S、N100DおよびV132I、
(15)I61L、E77R、Q82N、K83R、E84G、V93L、D95E、L96T、K98R、N100DおよびV132L、
(16)I61V、E77N、Q82S、K83R、E84HおよびV93A、
(17)I61V、V63I、E77V、K83R、E84D、D95E、L96T、K98RおよびN100E、
(18)I61L、V63I、E77V、K83R、D95E、L96S、K98R、N100DおよびG109R、
(19)I61V、E77L、Q82G、E84G、V93L、D95E、L96T、K98RおよびN100G、および、
(20)I61L、V63I、E77N、Q82GおよびE84G
のアミノ酸突然変異組合わせを順次に有する。
実施例1におけるヒトSIRPα変異体1の短縮ドメイン(野生型SIRPα短縮ドメインとも称する)および実施例1で得たヒトSIRPαドメインの突然変異体(すなわち、M1、M5、M12、M35、M37、M41、M57、M67、M81、M82、M84、M91、M99、M102、M111、M122、M126、M130、M135およびM145)を、それぞれヒトIgG1-Fc(そのアミノ酸配列が例えばSEQ ID NO:67で表される)と融合して発現させ、対応するSIRPα突然変異体1の短縮ドメイン-ヒトFc融合タンパク質(融合タンパク質と略称する)を取得し、これらの融合タンパク質をそれぞれSS002、SS002M1、SS002M5、SS002M12、SS002M35、SS002M37、SS002M41、SS002M57、SS002M67、SS002M81、SS002M82、SS002M84、SS002M91、SS002M99、SS002M102、SS002M111、SS002M122、SS002M126、SS002M130、SS002M135およびSS002M145と命名した。これらの融合タンパク質が、それぞれSEQ ID NO:61、21-40のいずれかで表されるアミノ酸配列を含有する。
例として、Biacore法でSS002、SS002M5、SS002M12、SS002M82、SS002M84、SS002M91、SS002M102、SS002M130などの各融合タンパク質とCD47分子の親和力を測定し、結果が例えば以下の表2に示した通りである。
融合タンパク質SS002およびSS002M91を例として、特異性認識活性を解析した。
融合タンパク質SS002およびSS002M91を例として、1mg/mlのSS002、SS002M91、牛乳(Beijing Bomeide Biotechnology Co., Ltd)、BSA(BOVOGEN)、CD19(Shenzhou Biological Technology Dexian Liability Company)、TROP2(Shenzhou Biological Technology Dexian Liability Company)、CD47(Beijing Maigeboer Biological Technology Co.,Ltd.)、CD38(Shenzhou Biological Technology Dexian Liability Company)、Gas6(R&D)などの各タンパク質およびAXL(ACRO Biosystems)でそれぞれELISAストリップを被覆し、4℃で一晩放置し、PBSTによる洗浄後、10%のウシ胎児血清を加えて、37℃で1時間ブロッキングし、それぞれSS002またはSS002M91を入れて、37℃で1時間反応し、PBSTによる洗浄後、ホースラディッシュペルオキシダーゼ標識ヤギ抗ヒトIgG二次抗体(Goat Anti human IgG HRP、Thermo Fisher Scientific)を加え、室温で30分間反応し、PBSTで板の洗浄を5回繰り返し、吸取紙上で残留液滴をできるだけ吸いきれ、1ウェルごとにTMB(eBioscience)を100 ml加えて、室温(20±5℃)で光のあたらない所に1〜5min放置し、1ウェルごとに2N H2SO4を100 mL加えて基質反応を停止させ、マイクロプレートリーダーで450nmにおけるOD値を読み取り、融合タンパク質と上記各タンパク質の結合能を解析した(例えば図7に示された)。
SS002M91を例として、CD47/SIRPαの相互作用を特異的に遮断する活性を解析し、米国の同類品種を発現するTTI-621(CN105073780Aを参照)を陽性対照とした。
融合タンパク質SS002とSS002M91を例として、腫瘍細胞表面のCD47分子の認識活性解析を行った。
SS002およびSS002M91を例として、CD47抗体Hu5F9-G4を(Guerriero J L、Sotayo A、Ponichtera H E、et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.[J]. Nature、2017、543(7645):428.432およびGholamin S、Mitra SS、Feroze AH et al. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci. Transl. Med 2017を参照)対照として、血液凝固活性解析を行った。
融合タンパク質SS002M91を例として、インビボ抗腫瘍活性解析を行った。
融合タンパク質SS002M91を例として、B-NSGマウスをモデルとし、インビボ安全性予備評価を行った。
実施例2における融合タンパク質構築方法によれば、実施例1で得られたSIRPαドメインの突然変異体M1、M5、M12、M35、M37、M41、M57、M67、M81、M82、M84、M91、M99、M102、M111、M122、M126、M130、M135およびM145をそれぞれヒトIgG4-Fc(そのアミノ酸配列がSEQ ID NO:68に示された)と融合して発現させ、対応するSIRPα突然変異体1の短縮ドメイン-ヒトFc融合タンパク質(融合タンパク質と略称する)を得て、これらの融合タンパク質をそれぞれSS002M1G4、SS002M5G4、SS002M12G4、SS002M35G4、SS002M37G4、SS002M41G4、SS002M57G4、SS002M67G4、SS002M81G4、SS002M82G4、SS002M84G4、SS002M91G4、SS002M99G4、SS002M102G4、SS002M111G4、SS002M122G4、SS002M126G4、SS002M130G4、SS002M135G4およびSS002M145G4(そのアミノ酸配列がそれぞれSEQ ID NO:41-60で表される)と命名した。
SS002M91G4を例として、実施例8における血液凝固反応測定の方法を参照しながら、IgG4 Fcに基づく上記融合タンパク質の血液凝固反応を評価した。健常ドナー由来の全血によってヒト赤血球を調製した。全血を、リン酸塩緩衝液(PBS)で5倍希釈後、3回洗浄して、新鮮な1%の赤血球溶液を調製した。血液凝固プレートにおける各穴に、50μLの濃度の異なる融合タンパク質SS002M91G4、陽性対照TTI-621および抗CD47抗体Hu5F9-G4を入れて、また、各穴にそれぞれ1%の赤血球溶液を50μL加え、軽く均一に混合し、37℃、5%CO2で一晩インキュベートした。一晩インキュベート後、上記プレートを画像判読した。判読標準は、赤血球を全て凝集させ、穴の底部に沈み込ませ、敷き広げてメッシュ状に平らになれば、100% の凝集(++++)とし、赤血球を穴の底部に沈み込ませ、ドット状になれば、非凝集(-)とした。
SS002M91G4を例として、Jurkat-CSR細胞(ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd.)系譜を利用して、TTI-621を陽性対照としてIgG4 Fcに基づく上記融合タンパク質の生物活性を評価した。
抑制率%=(OD450(試料)−OD450(ブランク)/ (OD450(Jurkat-CSR)−OD450(ブランク))×100
融合タンパク質SS002M91、SS002M91G4を例として、インビボ抗腫瘍活性および赤血球血小板の影響を解析した。
Claims (24)
- CD47タンパク質に特異的に結合し、且つ、以下
(a)1×10-8Mまたはより低いKD値でCD47タンパク質に結合し、
(b)CD47タンパク質とSIRPαとの相互作用を特異的に遮断し、
(c)血液凝固反応を起こさなく、および
(d)腫瘍または腫瘍細胞の成長および/または増殖を抑制する特性の少なくとも一つを含む、
融合タンパク質。 - 前記CD47タンパク質は、ヒトCD47タンパク質である、
請求項1に記載の融合タンパク質。 - 前記CD47タンパク質に特異的に結合することができるヒトSIRPαドメインおよび免疫グロブリンFc領域を含有し、ここで、前記ヒトSIRPαドメインと前記免疫グロブリンFc領域が直接的または間接的に連結している、
請求項1〜2のいずれか1項に記載の融合タンパク質。 - 前記ヒトSIRPαドメインは、ヒトSIRPαの細胞外ドメイン、その断片、またはその中で1個または複数のアミノ酸に置換されたその突然変異体を含む、
請求項3に記載の融合タンパク質。 - 前記ヒトSIRPαドメインは、ヒトSIRPαのIgVドメイン、その断片、またはその中で1個または複数のアミノ酸に置換されたその突然変異体を含む、
請求項3〜4のいずれか1項に記載の融合タンパク質。 - 前記ヒトSIRPαドメインは、ヒトSIRPα変異体1のドメイン、その断片、またはその中で1個または複数のアミノ酸に置換されたその突然変異体を含む、
請求項3〜5のいずれか1項に記載の融合タンパク質。 - 前記ヒトSIRPαドメインは、ヒトSIRPα変異体1における33〜149番目のアミノ酸残基、その断片、またはその中で1個または複数のアミノ酸に置換されたその突然変異体を含む、
請求項3〜6のいずれか1項に記載の融合タンパク質。 - 前記突然変異体は、I61、V63、E77、Q82、K83、E84、V93、D95、D96、K98、N100、R107、G109およびV132の群から選ばれる1個または複数の残基にアミノ酸置換を有する、
請求項7に記載の融合タンパク質。 - 前記突然変異体は、R22C、I29L、I61L/V/F、V63I、E77I/N/Q/K/H/M/R/N/V/L、Q82S/R/G/N、K83R、E84K/H/D/R/G、V93L/A、D95H/R/E、D96S/T、K98R、N100G/K/D/E、R107N/S、G109R/HおよびV132L/R/I/Sの群から選ばれるアミノ酸置換を1個または複数有する、
請求項8に記載の融合タンパク質。 - 前記ヒトSIRPαドメインは、SEQ ID NO: 1-20、62-65のいずれかで表されるアミノ酸配列を含有する、
請求項3〜9のいずれか1項に記載の融合タンパク質。 - 前記免疫グロブリンFc領域は、IgGのFc領域を有する、
請求項3〜10のいずれか1項に記載の融合タンパク質。 - 前記IgGは、IgG1および/またはIgG4の群から選ばれる、
請求項11に記載の融合タンパク質。 - 前記ヒトSIRPαドメインは、前記免疫グロブリンFc領域のN端に位置する、
請求項3〜12のいずれか1項に記載の融合タンパク質。 - 前記免疫グロブリンFc領域は、SEQ ID NO: 67-68のいずれかで表されるアミノ酸配列を含有する、
請求項3〜13のいずれか1項に記載の融合タンパク質。 - SEQ ID NO:21-61のいずれかで表されるアミノ酸配列を含有する、
請求項1〜14のいずれか1項に記載の融合タンパク質。 - 請求項1〜15のいずれか1項に記載の融合タンパク質をコードする、
核酸分子。 - 請求項16に記載の核酸分子を含む、
ベクター。 - 請求項16に記載の核酸分子または請求項17に記載のベクターを含む、
宿主細胞。 - 前記融合タンパク質を発現させる条件で、請求項18に記載の宿主細胞を培養することを含む、
請求項1〜15のいずれか1項に記載の融合タンパク質を調製する方法。 - 請求項1〜15のいずれか1項に記載の融合タンパク質、請求項16に記載の核酸分子、請求項17に記載のベクターおよび/または請求項18に記載の宿主細胞、および任意選択で薬学的に許容可能なアジュバントを含む、
組成物。 - 腫瘍または自己免疫疾患の予防または治療のための医薬品および/またはキットの調製における請求項1〜15のいずれか1項に記載の融合タンパク質、請求項16に記載の核酸分子、請求項17に記載のベクター、請求項18に記載の宿主細胞および/または請求項20に記載の組成物の用途。
- 前記腫瘍は、CD47陽性血液腫瘍および/またはCD47陽性固形腫瘍の群から選ばれる、
請求項21に記載の用途。 - 前記自己免疫疾患は、クローン病、アレルギー性喘息および/または関節リウマチの群から選ばれる、
請求項21に記載の用途。 - 請求項1〜15のいずれか1項に記載の融合タンパク質または請求項20に記載の組成物を投与することを含む、
CD47タンパク質とSIRPαとの相互作用を遮断する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810343482.9 | 2018-04-17 | ||
CN201810343482.9A CN110386984B (zh) | 2018-04-17 | 2018-04-17 | 结合cd47蛋白的融合蛋白及其应用 |
PCT/CN2019/082863 WO2019201236A1 (zh) | 2018-04-17 | 2019-04-16 | 结合cd47蛋白的融合蛋白及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021520830A true JP2021520830A (ja) | 2021-08-26 |
Family
ID=68239336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020556859A Pending JP2021520830A (ja) | 2018-04-17 | 2019-04-16 | Cd47タンパク質に結合する融合タンパク質およびその使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11891423B2 (ja) |
EP (1) | EP3795595A4 (ja) |
JP (1) | JP2021520830A (ja) |
KR (1) | KR20210003766A (ja) |
CN (2) | CN110386984B (ja) |
AU (1) | AU2019256177A1 (ja) |
BR (1) | BR112020021294A2 (ja) |
CA (1) | CA3097417A1 (ja) |
SG (1) | SG11202010237RA (ja) |
TW (1) | TWI822760B (ja) |
WO (1) | WO2019201236A1 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220047277A (ko) | 2019-07-16 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
JP7371243B2 (ja) | 2019-10-18 | 2023-10-30 | フォーティ セブン, インコーポレイテッド | 骨髄異形成症候群及び急性骨髄性白血病を治療するための併用療法 |
CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
IL294032A (en) | 2019-12-24 | 2022-08-01 | Carna Biosciences Inc | Compounds that regulate diacylglycerol kinase |
CA3169451A1 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
CN111253482B (zh) * | 2020-02-18 | 2021-11-30 | 中国人民解放军军事科学院军事医学研究院 | SIRPa变体、融合蛋白、及其应用 |
CN111808183B (zh) * | 2020-07-25 | 2022-07-08 | 北京吉尔麦迪生物医药科技有限公司 | 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白 |
KR102398032B1 (ko) * | 2020-09-22 | 2022-05-19 | 비피진 주식회사 | 암 치료를 위한 5''-뉴클레오티다아제 변이체 |
KR20230157388A (ko) | 2021-03-12 | 2023-11-16 | 멘두스 비.브이. | 백신접종의 방법 및 cd47 차단의 용도 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
TW202330504A (zh) | 2021-10-28 | 2023-08-01 | 美商基利科學股份有限公司 | 嗒𠯤—3(2h)—酮衍生物 |
AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
CN116143902A (zh) * | 2021-11-19 | 2023-05-23 | 杭州尚健生物技术有限公司 | SIRPα变体及其应用 |
US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
KR20230105583A (ko) * | 2022-01-04 | 2023-07-11 | 비피진 주식회사 | 5'-뉴클레오티다아제 변형 단백질을 암호화하는 암 치료를 위한 폴리뉴클레오티드 |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016501896A (ja) * | 2012-12-17 | 2016-01-21 | トリリアム・セラピューティクス・インコーポレイテッドTrillium Therapeutics Inc. | SIRPアルファ−Fc融合体でのCD47+疾患細胞の治療 |
WO2017027422A1 (en) * | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
JP2017525698A (ja) * | 2014-08-15 | 2017-09-07 | メルク パテント ゲーエムベーハー | Sirp−アルファ免疫グロブリン融合タンパク質 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2379584A1 (en) | 2008-12-19 | 2011-10-26 | Novartis AG | Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
PL2995315T3 (pl) * | 2009-05-15 | 2024-04-22 | University Health Network | Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie sirp alfa-cd47 |
SI3063275T1 (sl) * | 2013-10-31 | 2020-02-28 | Resolve Therapeutics, Llc | Terapevtske fuzije nukleaza-albumin in postopki |
CN106146670B (zh) * | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术(上海)有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
WO2018014068A1 (en) * | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Attenuated type i ifn cd47 combination therapy |
CA3071193A1 (en) * | 2017-07-26 | 2019-01-31 | Forty Seven, Inc. | Anti-sirp-alpha antibodies and related methods |
-
2018
- 2018-04-17 CN CN201810343482.9A patent/CN110386984B/zh active Active
-
2019
- 2019-04-16 WO PCT/CN2019/082863 patent/WO2019201236A1/zh unknown
- 2019-04-16 SG SG11202010237RA patent/SG11202010237RA/en unknown
- 2019-04-16 CA CA3097417A patent/CA3097417A1/en active Pending
- 2019-04-16 JP JP2020556859A patent/JP2021520830A/ja active Pending
- 2019-04-16 US US17/048,202 patent/US11891423B2/en active Active
- 2019-04-16 TW TW108113225A patent/TWI822760B/zh active
- 2019-04-16 KR KR1020207031110A patent/KR20210003766A/ko not_active Application Discontinuation
- 2019-04-16 EP EP19789512.1A patent/EP3795595A4/en active Pending
- 2019-04-16 CN CN201980026165.7A patent/CN111989346A/zh active Pending
- 2019-04-16 BR BR112020021294-6A patent/BR112020021294A2/pt unknown
- 2019-04-16 AU AU2019256177A patent/AU2019256177A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016501896A (ja) * | 2012-12-17 | 2016-01-21 | トリリアム・セラピューティクス・インコーポレイテッドTrillium Therapeutics Inc. | SIRPアルファ−Fc融合体でのCD47+疾患細胞の治療 |
JP2017525698A (ja) * | 2014-08-15 | 2017-09-07 | メルク パテント ゲーエムベーハー | Sirp−アルファ免疫グロブリン融合タンパク質 |
WO2017027422A1 (en) * | 2015-08-07 | 2017-02-16 | Alexo Therapeutics Inc. | Constructs having a sirp-alpha domain or variant thereof |
Non-Patent Citations (2)
Title |
---|
LEE WY. ET AL.: "Novel Structural Determinants on SIRP alfa that Mediate Binding to CD47", J IMMUNOL. 2007, VOL. 179, NO. 11, P. 7741-7780, JPN6023009566, ISSN: 0005012208 * |
WEISKOPF K. ET AL.: "Engineered SIRP alpha Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies", SCIENCE, 2013, VOL. 341, NO. 6141, P. 88-91, JPN6023009565, ISSN: 0005012209 * |
Also Published As
Publication number | Publication date |
---|---|
SG11202010237RA (en) | 2020-11-27 |
WO2019201236A1 (zh) | 2019-10-24 |
US11891423B2 (en) | 2024-02-06 |
EP3795595A4 (en) | 2022-03-16 |
TW201943728A (zh) | 2019-11-16 |
TWI822760B (zh) | 2023-11-21 |
CN111989346A (zh) | 2020-11-24 |
US20210171593A1 (en) | 2021-06-10 |
KR20210003766A (ko) | 2021-01-12 |
CN110386984A (zh) | 2019-10-29 |
EP3795595A1 (en) | 2021-03-24 |
CN110386984B (zh) | 2022-04-22 |
AU2019256177A1 (en) | 2020-11-26 |
BR112020021294A2 (pt) | 2021-01-26 |
CA3097417A1 (en) | 2019-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021520830A (ja) | Cd47タンパク質に結合する融合タンパク質およびその使用 | |
US11926671B2 (en) | Antibodies and polypeptides directed against CD127 | |
BR112019014694A2 (pt) | anticorpos anti-cd47 e usos dos mesmos | |
JP6105146B2 (ja) | Pan−ELR+CXCケモカイン抗体 | |
EA023665B1 (ru) | АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ | |
BR112016028755B1 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo,macromolécula, molécula de ácido nucleico, composição farmacêutica, uso de uma macromolécula, e, métodos para fabricar um anticorpo e para selecionar um anticorpo | |
CN110520441A (zh) | 抗TGF-β抗体及其用途 | |
CN103772504B (zh) | 人源化抗表皮生长因子受体抗体及其用途 | |
CN108135933A (zh) | 含有活动精子结构域的蛋白质2和癌症 | |
KR20170018814A (ko) | Il-21에 특이적인 결합 분자 및 이들 용도 | |
JP2022518519A (ja) | 新規二重特異性抗体分子及びpd-l1とlag-3と同時に結合する二重特異性抗体 | |
WO2021254481A1 (zh) | 抗Claudin18.2抗体以及其用途 | |
WO2019238074A1 (zh) | 一种高亲和力高生物活性的lag-3抗体及其应用 | |
RU2787521C2 (ru) | Связывание слитого белка с белком cd47 и его применение | |
JP7346576B2 (ja) | 抗ox40モノクローナル抗体とその応用 | |
WO2023088429A1 (zh) | SIRPα变体及其应用 | |
CN112079922B (zh) | 抗人p40蛋白域抗体及其用途 | |
JP2023506923A (ja) | イヌインターロイキン-4受容体α抗体 | |
CN116143902A (zh) | SIRPα变体及其应用 | |
WO2024062073A1 (en) | Treatment and prevention of cancer using vista antigen-binding molecules | |
WO2023041745A1 (en) | Treatment and prevention of cancer using vista antigen-binding molecules | |
OA19665A (en) | Antibodies and polypeptides directed against CD127. | |
BR112016029734B1 (pt) | Anticorpo isolado ou fragmento de ligação ao antígeno deste e uso do mesmo, composição farmacêutica e método para detecção de níveis de expressão de il-21 em uma amostra |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201026 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201112 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220304 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230314 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230614 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230711 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231110 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231115 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20231201 |